1REINCKE M. Mutations in adrenocortical tumors [J]. Horm Met Res, 1998, 30(6 -7 ) :447 - 455.
2TUPIKOWSKI W, BEDNAREK-TUPIKOWSKA G, FLORCZAK A. Adrenocortical carcinoma and its treatment [J] . Postepy Hig Med Dosw(Online), 2004, 58: 27-36.
3RATTAN S I, CLARK B F. Understanding and modulating ageing [J] . IUBMB Life,2005, 57 (4 - 5) :297 - 304.
4MACIEIRA-COELHO A. The biology of conformation in the regulation of the senescent and transformed cell phenotypes[J]. J Soc Biol,2004, 198(4):435-439.
5DIMRI G P. What has senescence got to do with cancer [J]? Cancer Cell,2005, 7(6) :505 -512.
6HORNSBY P J. Replicative senescence and cancer [J]. Cancer Treat Res,2005, 124:53 -73.
7GILLEY D, TANAKA H, HERBERT B S.Telomere dysfunction in aging and cancer[J] . Int J Biochem Cell Biol, 2005, 37(5) :1000 - 1013.
8LIU L, LAI S, ANDREWS L G, et al.Genetic and epigenetic modulation of telomerase activity in development and disease [J]. Gene,2004, 340 (1) : 1 - 10.
9HIYAMA T, YOKOZAKI H, KITADAI Y,et al. Analysis of expression of human telomerase RNA in gastric precancerous and cancerous lesions by using in situ mRNA hybridization [J] . Nippon Rinsho, 1998,56(5):1190 - 1193.
10REBBAA A. Targeting senescence pathways to reverse drug resistance in cancer [J].Cancer Lett, 2005, 219 ( 1 ) : 1 - 13.
二级参考文献4
1[3]Gupta D, Shidham V, Holden J, et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms [J]. Appl Immunohistochem Mol Morphol, 2001;9(3):215-221.
2[4]Eguchi T, Tokuyama A, Tanaka Y, et al. Hypoglycemia associated with the production of insulin-like growth factor II in adrenocortical carcinoma [J]. Intern Med, 2001;40(8):759-763.
3[5]Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors [J]. Cancer Res, 2001;61(18):6762-6767.
4[6]Salmenkivi K, Haglund C, Ristimaki A, et al. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas [J]. J Clin Endocrinol Metab, 2001;86(11):5615-5619.
2Barksdale S K.Carcinosarcoma of the adrenal corex presenting with mineralo-corticoid excess[J].AmJ Surg Pathol,1993,17(9):941.
3Honigschnabl S,Gallo S,Niederle B,et al.How accurate is MR imaging in characterization of adrenal masses:update of a longterm study[J].Eur J Radiol,2002,41(2):113-122.
4Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma[J]. Clin Endocrinol (Oxf), 2004, 60(3) :273-287.
5Fulmer B R. Diagnosis and management of adrenal cortical carcinoma[J]. Curr Urol Rep, 2007, 8 (1) : 77-82.
6Schulick R D, Brennan M F. Adrenocortical carcinoma [J]. World J Urol, 1999, 17(1):26-34.
7Schulick R D, Brennan M F. Long-term survival after complete resection and repeat resection in patients with adrenocortical careinoma[J]. Ann Surg Oncol, 1999, 6 (8) :719-726.
8Bilimoria K Y, Shen W T, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utiliza- tion and prognostic factors[J]. Cancer, 2008, 113 (11) :3130-3136.
9Fassnacht M, Allolio B. Clinical management of adre- nocortieal carcinoma[J]. Best Pract Res Clin Endocrinol Metab, 2009, 23(2):273-289.
10Lebastehi A H, Kunstman J W, Carling T. Adreno2 cortical carcinoma: current therapeutic state-of-the-art [J]. J Oncol, 2012: 234726.
